NFL Biosciences Publishes Its 2026 Financial Agenda

About this update from Nfl Biosciences Sa

MONTPELLIER, France, February 19, 2026 --( BUSINESS WIRE )--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda for 2026. *Press releases will be published after the close of the stock market The calendar is provided for information purposes only and may be subject to modification. About NFL Biosciences: www.nflbiosciences.com NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an "Innovative Company" eligible for FCPI investment. More information on www.nflbiosciences.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260219628385/en/ Contacts NewCap Investor Relations / Media Relations Mathilde Bohin / Arthur Rouillé Tel.: 01 44 71 94 94 E-mail : [email protected] NFL Biosciences Bruno Lafont Tél.: 04 11 93 76 67 E-mail : [email protected]

View stock analysis, news, and events for Nfl Biosciences Sa